our pipeline

We are advancing a pipeline of AlloCAR TTM candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Our AlloCAR T portfolio includes rights to 15 preclinical CAR T cell therapy targets licensed from Cellectis and U.S. rights to clinical candidates ALLO-501 and UCART19 licensed from Servier, currently in Phase 1 development for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) and relapsed/refractory acute lymphoblastic leukemia (ALL), respectively.